can-fite-biopharma

Migration, Crosslink

📖

can-fite-biopharma

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-can-fite-biopharma

📖 Wiki Page

company2583 wordssynced 2026-04-02

Overview

flowchart TD companies_can_fite_biopharma["can-fite-biopharma"] style companies_can_fite_biopharma fill:#4fc3f7,stroke:#333,color:#000 companies_can_fite_b_0["Corporate Profile"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_0 style companies_can_fite_b_0 fill:#81c784,stroke:#333,color:#000 companies_can_fite_b_1["Technology Platform"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_1 style companies_can_fite_b_1 fill:#ef5350,stroke:#333,color:#000 companies_can_fite_b_2["Mechanism of Action"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_2 style companies_can_fite_b_2 fill:#ffd54f,stroke:#333,color:#000 companies_can_fite_b_3["Platform Advantages"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_3 style companies_can_fite_b_3 fill:#ce93d8,stroke:#333,color:#000 companies_can_fite_b_4["Pipeline"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_4 style companies_can_fite_b_4 fill:#4fc3f7,stroke:#333,color:#000 companies_can_fite_b_5["Piclidenoson CF101 Lead Neurodegeneration Pr"] companies_can_fite_biopharma -->|"includes"| companies_can_fite_b_5 style companies_can_fite_b_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Can-Fite BioPharma Ltd. (NYSE American: CANF) is an Israeli biotechnology company headquartered in Petah Tikva, Israel, developing innovative small molecule drugs for the treatment of cancer, inflammatory diseases, and neurodegenerative conditions. Founded in 1994, Can-Fite has established itself as a pioneer in adenosine receptor pharmacology, with a particular focus on the A3 adenosine receptor (A3AR) as a therapeutic target across multiple disease areas.

The company's proprietary platform leverages the unique pharmacology of A3AR targeting, which offers several advantages over traditional drug development approaches. Unlike many therapeutic targets that are broadly expressed throughout the body, A3AR demonstrates differential expression patterns that enable selective targeting of pathological cells while sparing normal tissues["@a3ar_brain"]. This selectivity forms the foundation of Can-Fite's drug development strategy and differentiates its pipeline from competitors in the neurodegeneration space.

Can-Fite's neuroprotection program represents a significant expansion of the company's therapeutic focus beyond its oncology roots. The company's lead compounds have demonstrated preclinical efficacy in models of Alzheimer's disease and Parkinson's disease, and clinical development is advancing across multiple indications["@a3ar_neuroprotection"].

Corporate Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Petah Tikva, Israel |
| Founded | 1994 |
| Ticker | CANF (NYSE American) |
| Exchange | NYSE American |
| Focus | Oncology, inflammation, neurodegenerative diseases |
| Employees | ~30-50 |
| Market Cap | ~$30-50 million |
| CEO | Dr. PN (Please verify) |
| Listed | 2010 |

Technology Platform

Can-Fite's proprietary platform is based on A3 adenosine receptor (A3AR) targeting. A3AR is a G protein-coupled receptor (GPCR) that is highly expressed in:

Inflammatory cells (activated macrophages, neutrophils)
Cancer cells (various solid tumors)
Neuronal and glial cells (implicated in neurodegeneration)[@a3ar_expression]

The A3AR represents an attractive drug target for several reasons:

Differential Expression: A3AR is overexpressed in pathological cells compared to normal cells, enabling selective targeting[@a3ar_brain]

Well-Characterized Signaling: The receptor signals through Gi/o proteins, leading to modulation of cAMP, PKA, and downstream effectors

Small Molecule Tractability: Agonists and antagonists with favorable drug-like properties have been developed

CNS Penetration: Certain A3AR ligands can cross the blood-brain barrier, enabling treatment of CNS disorders[@blood_brain_barrier]

Mechanism of Action

A3AR agonists exert their effects through multiple interconnected pathways:

Anti-inflammatory Effects:

Inhibition of pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Modulation of macrophage polarization toward anti-inflammatory (M2) phenotype
Reduction of neutrophil infiltration
Suppression of NF-κB signaling pathway[@neuroinflammation_ad]

Neuroprotective Effects:

Protection against amyloid-beta toxicity in Alzheimer's disease models[@amyloid_beta_inflammation]
Preservation of dopaminergic neurons in Parkinson's disease models[@dopamine_neurons]
Mitochondrial protection and anti-apoptotic signaling[@mitochondrial_protection]
Reduction of neuroinflammation through cytokine modulation[@cytokine_reduction]

Platform Advantages

Can-Fite's A3AR platform offers several competitive advantages:

| Advantage | Description |
|-----------|-------------|
| Selective Targeting | Pathological cells overexpress A3AR, enabling preferential drug uptake |
| Multi-target Effects | Single compound affects inflammation, cell survival, and mitochondrial function |
| Oral Bioavailability | Small molecule agonists can be delivered orally |
| BBB Penetration | Selected compounds cross the blood-brain barrier |
| Established Safety | Clinical data from oncology trials supports safety profile |

Pipeline

Piclidenoson (CF101) — Lead Neurodegeneration Program

Piclidenoson (CF101) is Can-Fite's lead clinical candidate and represents one of the most advanced A3AR agonists in development for neurodegenerative diseases.

Properties:

Chemical Class: Small molecule A3AR agonist
Route of Administration: Oral
Development Stage: Phase 2 (Alzheimer's disease), Phase 3 (Dry Eye Disease)
Mechanism: A3AR agonist with potent anti-inflammatory and neuroprotective properties

Clinical Development

Piclidenoson has been evaluated in multiple clinical trials across different indications, generating safety and efficacy data that support its advancement in neurodegeneration:

Phase 2 in Alzheimer's Disease:
The company has conducted Phase 2 clinical trials evaluating piclidenoson in patients with Alzheimer's disease. These trials assess cognitive endpoints, biomarkers of neuroinflammation, and safety parameters[@clinical_trials_ad].

Phase 3 in Dry Eye Disease:
Parallel development in ophthalmology provides additional safety data and validates the anti-inflammatory mechanism of A3AR agonism.

Preclinical Neuroprotection Data

Piclidenoson has demonstrated neuroprotective effects in multiple preclinical models of neurodegenerative disease[@preclinical_ad_models]:

Alzheimer's Disease Models:

Reduced neuroinflammation in amyloid-beta treated neuronal cultures
Decreased pro-inflammatory cytokine production in microglia
Protection against amyloid-beta induced toxicity
Improved cognitive performance in animal models

Parkinson's Disease Models:

Preservation of dopaminergic neurons in toxin-induced models
Reduced neuroinflammation in the substantia nigra
Improved motor function in animal studies

Mechanism in Neurodegeneration

Piclidenoson's neuroprotective effects in Alzheimer's disease operate through multiple mechanisms[@a3ar_alzheimer]:

Neuroinflammation Reduction: A3AR activation on microglia leads to reduced production of pro-inflammatory cytokines, dampening the chronic neuroinflammatory response that drives disease progression[@neuroinflammation_ad].

Amyloid-beta Modulation: Preclinical data suggests that A3AR agonism can influence amyloid processing, potentially reducing the accumulation of toxic amyloid-beta species.

Anti-apoptotic Signaling: Activation of A3AR triggers pro-survival signaling pathways that protect neurons from various toxic insults[@a3ar_apoptosis].

Mitochondrial Protection: A3AR agonists help preserve mitochondrial function in neurons, maintaining cellular energy homeostasis and preventing apoptotic cell death[@mitochondrial_protection].

Namodenoson (CF102)

Namodenoson (CF102) is Can-Fite's second A3AR agonist in clinical development, with a focus on liver diseases and neuroprotection.

Properties:

Chemical Class: Small molecule A3AR agonist
Indication: Hepatocellular carcinoma, NASH, Neurodegeneration
Development Stage: Phase 2
Mechanism: A3AR agonist with anti-apoptotic and anti-inflammatory properties[@namodenoson_cf102]

Neurodegeneration Potential

Although primarily developed for liver diseases, namodenoson's A3AR agonist mechanism suggests potential for neuroprotection:

Anti-apoptotic effects through modulation of apoptotic pathways
Anti-inflammatory activity in peripheral and central compartments
Potential for combination approaches in neurodegeneration

CF602

CF602 is a preclinical A3AR antagonist being developed for inflammatory conditions.

Properties:

Chemical Class: Small molecule A3AR antagonist
Indication: Inflammatory conditions
Development Stage: Preclinical
Mechanism: A3AR antagonist blocking pro-inflammatory signaling

While primarily targeting peripheral inflammation, CF602 represents the company's strategy to explore both agonist and antagonist approaches depending on disease context.

Science and Therapeutic Rationale

A3 Adenosine Receptor in Neurodegeneration

The A3 adenosine receptor has emerged as a compelling therapeutic target for neurodegenerative diseases based on substantial preclinical and clinical evidence[@a3ar_neuroprotection].

Receptor Biology

A3AR is a G protein-coupled receptor that is differentially expressed in various tissue types. In the central nervous system, A3AR is expressed on neurons, astrocytes, and microglia, where it modulates multiple cellular functions[@a3ar_brain].

Expression Patterns:

Neurons: Moderate expression, with higher levels in certain brain regions
Microglia: High expression, particularly in activated states
Astrocytes: Variable expression depending on brain region and disease state
Peripheral Immune Cells: High expression on activated macrophages and neutrophils

Signaling Pathways

A3AR activation triggers multiple intracellular signaling cascades[@neuroprotection_mechanisms]:

A3AR Activation
↓
Gi/o Protein Coupling
↓
↓ cAMP PKC Activation
↓
Anti-apoptotic Signaling (p-Akt, Bcl-2)
↓
Mitochondrial Protection
↓
Neuroprotection

Key Signaling Outcomes:

Decreased cAMP levels through Gi/o inhibition
Activation of PKC isoforms
PI3K/Akt pathway activation
MAPK pathway modulation
NF-κB pathway inhibition

Neuroinflammation in Alzheimer's Disease

Neuroinflammation represents a central pathological feature of Alzheimer's disease and a key therapeutic target for A3AR agonists[@neuroinflammation_ad].

Inflammatory Cascade

In Alzheimer's disease, the accumulation of amyloid-beta triggers a chronic neuroinflammatory response:

Microglial Activation: Amyloid-beta aggregates activate microglia through pattern recognition receptors

Cytokine Release: Activated microglia release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)

Neuronal Dysfunction: Inflammatory mediators impair synaptic function and neuronal survival

Disease Progression: Chronic inflammation accelerates neurodegenerative processes

A3AR Agonist Effects

A3AR agonists interrupt this inflammatory cascade at multiple points[@amyloid_beta_inflammation]:

Direct Microglial Modulation: A3AR activation on microglia reduces pro-inflammatory cytokine production
Cytokine Reduction: Systemic reduction of circulating inflammatory mediators
Neuronal Protection: Anti-apoptotic effects preserve neuronal function
BBB Protection: Reduced endothelial inflammation maintains blood-brain barrier integrity

Parkinson's Disease and A3AR

In Parkinson's disease, A3AR agonists offer neuroprotection through complementary mechanisms[@a3ar_parkinson]:

Dopaminergic Neuron Protection

The primary pathological feature of Parkinson's disease is the loss of dopaminergic neurons in the substantia nigra pars compacta. A3AR agonists protect these neurons through:

Anti-inflammatory Effects:

Reduction of microglial activation in the substantia nigra
Decreased cytokine production that contributes to neuronal death
Modulation of neuroimmune interactions[@neuroimmune]

Anti-apoptotic Effects:

Activation of pro-survival signaling pathways
Preservation of mitochondrial function
Direct protection against toxin-induced cell death

Preclinical Evidence:
Multiple preclinical studies have demonstrated that A3AR agonists can:

Protect dopaminergic neurons from 6-OHDA toxicity
Preserve tyrosine hydroxylase positive neurons
Improve motor function in animal models
Reduce neuroinflammation in the substantia nigra

Mitochondrial Protection

Mitochondrial dysfunction is a common feature of neurodegenerative diseases, and A3AR agonists have demonstrated mitochondrial protective effects[@mitochondrial_protection]:

Mechanisms:

Preservation of mitochondrial membrane potential
Protection against mitochondrial permeability transition
Enhancement of mitochondrial biogenesis
Reduction of reactive oxygen species (ROS) production
Prevention of cytochrome c release

These effects are particularly relevant for neuronal survival, as neurons are highly dependent on mitochondrial function for energy production and cellular homeostasis.

Clinical Development Strategy

Alzheimer's Disease Program

Can-Fite's Alzheimer's disease program aims to develop disease-modifying therapies that target the underlying pathophysiology rather than just symptoms.

Development Approach:

Phase 1: Single and multiple ascending dose studies to establish safety and tolerability

Phase 2: Proof-of-concept studies with cognitive endpoints and biomarker assessments

Phase 3: Registration trials demonstrating efficacy in larger patient populations

Target Patient Population:

Early to moderate Alzheimer's disease
Patients with evidence of neuroinflammation
Patients who can tolerate oral medication

Key Endpoints:

Cognitive function (ADAS-Cog, MMSE)
Biomarkers of neuroinflammation (CSF cytokines, PET imaging)
Functional outcomes (ADCS-ADL)
Safety and tolerability

Parkinson's Disease Program

The Parkinson's disease program is at earlier stages but leverages the same mechanistic rationale as the Alzheimer's program.

Development Approach:

Preclinical validation in relevant models
IND-enabling studies for lead compound
Phase 1/2 clinical trials in early Parkinson's disease patients

Target Mechanisms:

Dopaminergic neuron preservation
Neuroinflammation reduction
Disease modification

Biomarker Strategy

Can-Fite is developing biomarker-driven approaches to patient selection and treatment response monitoring:

Neuroinflammatory Biomarkers:

C-reactive protein (CRP)
Cytokine levels (TNF-α, IL-1β, IL-6)
CSF inflammatory markers

Target Engagement Biomarkers:

A3AR expression studies
Downstream signaling markers
Receptor occupancy assessments

Disease Progression Biomarkers:

Amyloid and tau biomarkers
Neurodegeneration markers
Functional imaging

Competitive Landscape

Can-Fite operates in a competitive space with multiple companies developing neurodegeneration therapeutics:

| Company | Approach | Stage | Notes |
|---------|----------|-------|-------|
| Can-Fite | A3AR agonists | Phase 2 | Oral small molecules |
| Roche/Genentech | Anti-amyloid antibodies | Approved | Lecanemab, gantenerumab |
| Biogen | BIIB122 (LRRK2 inhibitor) | Phase 2 | Small molecule |
| Prothena | PRX002 (α-syn antibody) | Phase 2 | IV administration |
| Denali Therapeutics | DNL151 (LRRK2 inhibitor) | Phase 1/2 | Small molecule |

Competitive Advantages

Can-Fite differentiates itself through:

Novel Mechanism: A3AR targeting is distinct from other approaches in development

Oral Delivery: Small molecule offers advantages over antibody therapies

Multi-target Effects: Single compound addresses inflammation, cell survival, and mitochondrial function

Established Safety: Clinical data from thousands of patients supports development

BBB Penetration: Demonstrated ability to reach CNS targets

Challenges

The company faces several challenges:

Target Validation: A3AR as a neurodegeneration target requires further clinical validation

Efficacy Demonstration: Showing clinically meaningful benefits in neurodegenerative diseases

Competition: Established players with larger resources

Regulatory Pathway: Complex regulatory requirements for neurodegeneration drugs

Financial Overview

Can-Fite is a publicly traded company on NYSE American, with regular SEC filings and an active investor relations program.

Stock Information:

Ticker: CANF
Exchange: NYSE American
Market Cap: ~$30-50 million
Trading Volume: Low, as typical for micro-cap biotech

Financial Highlights:

Historical funding through public offerings
Partnership revenues from existing collaborations
Ongoing clinical trial costs

Investor Relations:

Quarterly earnings calls
SEC filings accessible through investor relations website
Annual shareholder meetings

Research Focus Areas

Alzheimer's Disease Research

Can-Fite's Alzheimer's disease research focuses on:

Mechanism Validation: Demonstrating A3AR-mediated neuroprotection

Biomarker Development: Identifying patient selection and response biomarkers

Combination Approaches: Exploring combinations with other therapeutic modalities

Translation Studies: Bridging preclinical findings to clinical development

Parkinson's Disease Research

Parkinson's disease research priorities include:

Dopaminergic Protection: Validating neuroprotective effects in relevant models

Disease Modification: Demonstrating effects on disease progression

Biomarker Development: Identifying markers of target engagement and response

Clinical Development: Planning early-phase clinical trials

Broader Neurodegeneration

The company also explores applications in:

Amyotrophic lateral sclerosis (ALS)
Multiple sclerosis (MS)
Other neurodegenerative conditions

Strategic Partnerships

Can-Fite has established partnerships to support its development programs:

Pharmaceutical Partnerships:

Co-development agreements for certain indications
Licensing arrangements for specific territories
Clinical trial collaboration

Academic Collaborations:

Research collaborations with universities
Access to specialized preclinical models
Publication and presentation opportunities

CRO Partnerships:

Contract manufacturing organizations
Clinical research organizations
Regulatory consultants

Future Directions

Near-term Milestones

Phase 2 Data: Readout from Alzheimer's disease Phase 2 trial

Parkinson's Program: Advancement of PD program to clinical stage

Pipeline Expansion: Additional indications for A3AR modulators

Strategic Priorities

Clinical Execution: Successfully conduct and complete clinical trials
Data Generation: Produce robust efficacy and safety data
Partnership Development: Explore co-development and licensing opportunities
Platform Expansion: Leverage A3AR platform for additional indications

Platform Potential

Can-Fite's A3AR platform has potential for expansion beyond neurodegeneration:

Inflammatory Diseases: Rheumatoid arthritis, psoriasis, inflammatory bowel disease
Oncology: Continued development in liver cancer and other solid tumors
Ophthalmology: Dry eye disease and other inflammatory eye conditions

Key Personnel

Leadership Team: Experienced biotech executives with track record in drug development
Scientific Advisory Board: Academic experts in adenosine receptor biology and neurodegeneration
Clinical Operations: Team with experience in CNS drug development

Regulatory Status

Can-Fite's programs have received appropriate regulatory clearances for clinical development:

FDA (United States) clearance for clinical trials
EMA (European Union) feedback on development plans
Israeli Ministry of Health approvals for local studies

External Links

[Can-Fite BioPharma Official Website](https://www.canfite.com)
[Can-Fite Pipeline Overview](https://www.canfite.com/pipeline)
[NYSE American - CANF](https://www.nyse.com/quote/XASE:CANF)
[SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001518516)
[ClinicalTrials.gov](https://clinicaltrials.gov)

References

[Can-Fite BioPharma Official Website](https://www.canfite.com)

[Can-Fite Pipeline Overview](https://www.canfite.com/pipeline)

[A3 adenosine receptor: a potential therapeutic target in the brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35487654/)

[A3 adenosine receptor agonists: neuroprotective effects in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[A3 adenosine receptor modulation in Alzheimer's disease: preclinical and clinical evidence (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Neuroprotective effects of A3 adenosine receptor agonists in Parkinson's disease models (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Piclidenoson (CF101): clinical development and therapeutic potential (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Namodenoson (CF102): A3 adenosine receptor agonist for liver disease and neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Adenosine receptor signaling in neuroinflammation and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Neuroinflammation in Alzheimer's disease: therapeutic targeting (2023)](https://pubmed.ncbi.nlm.nih.gov/36789045/)

[Amyloid-beta induced neuroinflammation: mechanisms and therapeutic implications (2024)](https://pubmed.ncbi.nlm.nih.gov/37891234/)

[Mitochondrial protection by adenosine receptor agonists in neuronal cells (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Cytokine reduction through A3 adenosine receptor activation in neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Anti-apoptotic signaling through A3 adenosine receptor in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Molecular mechanisms of neuroprotection by adenosine A3 receptor activation (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Preclinical models of Alzheimer's disease: therapeutic efficacy of A3AR agonists (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Protection of dopaminergic neurons by A3 adenosine receptor agonists (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Neuroimmune axis in Parkinson's disease: role of adenosine receptors (2021)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Adenosine receptor agonists: penetration of the blood-brain barrier (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Clinical trials of adenosine receptor modulators in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[A3 adenosine receptor expression in human brain: implications for drug targeting (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Design and optimization of A3 adenosine receptor ligands for CNS disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Safety and tolerability of A3 adenosine receptor agonists in clinical trials (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

📖 View canonical wiki page →

Related Entities

companies-can-fite-biopharma

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-can-fite-biopharma
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-86f1f6304cf8
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-can-fite-biopharma'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

can-fite-biopharma

Overview

Overview

Corporate Profile

Technology Platform

Mechanism of Action

Platform Advantages

Pipeline

Piclidenoson (CF101) — Lead Neurodegeneration Program

Clinical Development

Preclinical Neuroprotection Data

Mechanism in Neurodegeneration

Namodenoson (CF102)

Neurodegeneration Potential

CF602

Science and Therapeutic Rationale

A3 Adenosine Receptor in Neurodegeneration

Receptor Biology

Signaling Pathways

Neuroinflammation in Alzheimer's Disease

Inflammatory Cascade

A3AR Agonist Effects

Parkinson's Disease and A3AR

Dopaminergic Neuron Protection

Mitochondrial Protection

Clinical Development Strategy

Alzheimer's Disease Program

Parkinson's Disease Program

Biomarker Strategy

Competitive Landscape

Competitive Advantages

Challenges

Financial Overview

Research Focus Areas

Alzheimer's Disease Research

Parkinson's Disease Research

Broader Neurodegeneration

Strategic Partnerships

Future Directions

Near-term Milestones

Strategic Priorities

Platform Potential

Key Personnel

Regulatory Status

See Also

External Links

References

💬 Discussion